Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2763480 | 0.83 | MEN1 (0.45) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2762846 | 0.80 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL1502290 | 0.80 | MEN1 (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| Methylene Chloride SCHEMBL27848258 | 0.78 | MEN1 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL11057658 | 0.78 | MEN1 (0.63) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL3674393 | 0.78 | RAB9A (0.51) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL2763264 | 0.77 | MEN1 (0.43) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL8494650 | 0.76 | SMN1; SMN2 (0.47) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL27934590 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2ANPC1RAB9ASRD5A2 | |
| SCHEMBL1502389 | 0.76 | NPC1 (0.50) | MEN1KMT2ANPC1RAB9ASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777555-B2 | 3-(OPTIONALLY HYDROXYL)-4-(CYCLOPROPYLCARBONYL)-CUMENE INTERMEDIATE | MERRELL PHARMACEUTICALS, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS, INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020077482-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL DOW PHARMACEUTICALS INC. | 2002-06-20 | — | — | US | disclosed |
| US-6147216-A | Intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. (US) | 2000-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220496-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | MEN1 2722/4885KMT2A 1588/4885NPC1 2412/4885 |
| US-20020077482-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | MEN1 2671/4885KMT2A 1998/4885NPC1 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.